×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Clinical: Metformin for Parkinson's Disease - Phase 2/3 Trial (NCT0722
clinical
1,298 words
KG: metformin
Contents
Metformin for Parkinson's Disease - Phase 2/3 Trial (NCT07229651)
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.91
Transcriptional Autophagy-Lysosome Coupling
Score: 0.88
APOE-Dependent Autophagy Restoration
Score: 0.85
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.81
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.78
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.78
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Phase-Separated Organelle Targeting
Score: 0.73
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.73
Circadian Rhythm Entrainment of Reactive Astrocytes
Score: 0.72
Stress Granule Phase Separation Modulators
Score: 0.72
Retinal Vascular Microcirculation Rescue
Score: 0.72
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.71
Membrane Cholesterol Gradient Modulators
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
Lysosomal Enzyme Trafficking Correction
Score: 0.71
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.70
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
Arginine Methylation Enhancement Therapy
Score: 0.65
Pharmacological Enhancement of APOE4 Glycosylation
Score: 0.62
Vagal Afferent Microbial Signal Modulation
Score: 0.62
Low Complexity Domain Cross-Linking Inhibition
Score: 0.62
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.61
Brain Insulin Resistance with Glucose Transporter Dysfunctio
Score: 0.60
Digital Twin-Guided Metabolic Reprogramming
Score: 0.55
Show 25 more
Related Analyses (25)
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Show 20 more
Related Experiments (30)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Show 25 more
See Also (4)
AMPK (AMP-Activated Protein Kinase)
entity · KG edge: activates
Autophagy Enhancement Drug Screening for Neurodegenerat
experiment · KG edge: activates
Alzheimer Indonesia
institution · KG edge: associated_with
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: associated_with
Knowledge Graph (12 edges)
metformin
activates
AMPK
metformin
regulates
BMAL1
metformin
treats
Parkinson's disease
metformin
treats
Alzheimer's disease
metformin
treats
type 2 diabetes mellitus
metformin
inhibits
reactive oxygen species production
metformin
treats
epilepsy
metformin
therapeutic_target
Alzheimer's disease
metformin
treats
insulin sensitivity
metformin
inhibits
astrocyte senescence
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)